especially after researchers adjusted for other medications that can increase risk of skin cancer. However, the drug did not protect Black patients against squamous cell cancers, researchers found.

Checkpoint Therapeutics’ late entry into the PD-1/PD-L1 inhibitor category, cosibelimab, just got knocked back even further after it was turned down by the FDA as a treatment for skin cancer.

especially after researchers adjusted for other medications that can increase risk of skin cancer. However, the drug did not protect Black patients against squamous cell cancers, researchers found.

When looking at just the relationship between the diabetes drug and skin cancer risk without adjusting for other factors, patients had 54% lower odds of developing BCC and 35% lower odds of SCC.

Medtech company DermaSensor has claimed FDA approval for a handheld device, powered by artificial intelligence (AI), that can be used to detect skin cancer at the point of care. The eponymous ...